Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells

Dong,Lun; Meng,Fanyan; Wu,Ling; Mitchell,Allison  V.; Block,C.  James; Zhang,Bin; Craig,Douglas  B.; Jang,Hyejeong; Chen,Wei; Yang,Qifeng; Wu,Guojun

doi:10.3892/ijo.2017.4108

Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells

Authors:
- Lun Dong
- Fanyan Meng
- Ling Wu
- Allison V. Mitchell
- C. James Block
- Bin Zhang
- Douglas B. Craig
- Hyejeong Jang
- Wei Chen
- Qifeng Yang
- Guojun Wu
View Affiliations

Affiliations: Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA, Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn Mount Sinai School of Medicine, New York, NY 10029, USA, Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: August 30, 2017 https://doi.org/10.3892/ijo.2017.4108
Pages: 1320-1330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Though incidence of PI3K oncogenic mutation is prominent in breast cancer (20-30%), pharmacological targeting of this signaling pathway alone has failed to provide meaningful clinical benefit. To better understand and address this problem, we conducted genome-wide analysis to study the association of mutant PI3K with other gene amplification events. One of the most significant copy number gain events associated with PIK3CA mutation was the region within chromosome 17 containing HER2. To investigate the oncogenic effect and cell signaling regulation of co-occurring PIK3CA-H1047R and or HER2 gene, we generated cell models ectopically expressing mutant PIK3CA, HER2 or both genetic alterations. We observed that cells with both genetic alterations demonstrate increased aggressiveness and invasive capabilities than cells with either genetic change alone. Furthermore, we found that the combination of the HER2 inhibitor (CP-724714) and pan PI3K inhibitor (LY294002) is more potent than either inhibitor alone in terms of inhibition of cell proliferation and colony formation. Significantly, four cell signaling pathways were found in common for cells with HER2, mutant PIK3CA and cells with both genetic alterations through an Affymetric microarray analysis. Moreover, the cells with both genetic alterations acquired more significant replication stress as shown by enriched signaling pathways of cell cycle checkpoint control and DNA damage response signaling. Our study suggests co-occurrence of oncogenic HER2 and mutant PIK3CA cooperatively drives breast cancer progression. The cells with both genetic alterations obtain additional features of replication stress which could open new opportunity for cancer diagnostics and treatment.

View Figures

View References

1	Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 5:921–929. 2005. View Article : Google Scholar : PubMed/NCBI
2	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
3	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AkT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
4	Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair Bg, Lin C, et al: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
5	Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
6	Saal Lh, Holm K, Maurer M, Memeo L, Su T, Wang X, YU JS, Malmström PO, Mansukhani M, Enoksson J, et al: IK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65:2554–2559. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, et al: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7:R609–R616. 2005. View Article : Google Scholar : PubMed/NCBI
8	Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP and Wu G: Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat. 112:217–227. 2008. View Article : Google Scholar
9	Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC and Brugge JS: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65:10992–11000. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005. View Article : Google Scholar : PubMed/NCBI
11	Samuels Y, Diaz LA Jr, Schmidt-kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
12	Zhao JJ, Liu Z, Wang L, Shin E, Loda MF and Roberts TM: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA. 102:18443–18448. 2005. View Article : Google Scholar : PubMed/NCBI
13	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
15	De Laurentiis M, Cancello G, Zinno L, Montagna E, Malorni L, Esposito A, Pennacchio R, Silvestro L, Giuliano M, Giordano A, et al: Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol. 16(Suppl 4): iv7–iv13. 2005. View Article : Google Scholar : PubMed/NCBI
16	Li SG and Li L: Targeted therapy in HER2-positive breast cancer. Biomed Rep. 1:499–505. 2013. View Article : Google Scholar
17	Gajria D and Chandarlapaty S: HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
18	Rexer BN and Arteaga CL: Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications. Cancer Res. 73:3817–3820. 2013. View Article : Google Scholar : PubMed/NCBI
19	Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, et al: PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematol Oncol Stem Cell Ther. 7:142–148. 2014. View Article : Google Scholar : PubMed/NCBI
20	Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA and Arteaga CL: H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene. 29:5193–5203. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, et al: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA. 110:14372–14377. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M and Minami H: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 21:255–262. 2010. View Article : Google Scholar
23	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
24	Searl TJ and Silinsky EM: LY 294002 inhibits adenosine receptor activation by a mechanism independent of effects on PI-3 kinase or casein kinase II. Purinergic Signal. 1:389–394. 2005. View Article : Google Scholar
25	Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 269:5241–5248. 1994.PubMed/NCBI
26	Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, et al: Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci. 108:492–500. 2009. View Article : Google Scholar : PubMed/NCBI
27	Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, et al: Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res. 67:9887–9893. 2007. View Article : Google Scholar : PubMed/NCBI
28	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
29	Kim S, Han J, Lee SK, Koo M, Cho Dh, Bae Sy, Choi My, Kim JS, Kim JH, Choe JH, et al: Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. Cancer Lett. 314:147–154. 2012. View Article : Google Scholar
30	Chen JX, XU LL, Wang XC, Qin HY and Wang JL: Involvement of c-Src/STAT3 signal in EGF-induced proliferation of rat spermatogonial stem cells. Mol cell Biochem. 358:67–73. 2011. View Article : Google Scholar : PubMed/NCBI
31	Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros W, Mueller MD and YU JJ: correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep. 27:286–292. 2012.
32	Boyd DB: Insulin and cancer. Integr Cancer Ther. 2:315–329. 2003. View Article : Google Scholar
33	Müssig K and Häring HU: Insulin signal transduction in normal cells and its role in carcinogenesis. Exp Clin Endocrinol Diabetes. 118:356–359. 2010. View Article : Google Scholar : PubMed/NCBI
34	Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012.PubMed/NCBI
35	Rexer BN, Chanthaphaychith S, Dahlman K and Arteaga CL: Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2⁺ breast cancer cells. Breast Cancer Res. 16:R92014. View Article : Google Scholar
36	Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, et al: Dual HER2/IK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 14:2519–2526. 2015. View Article : Google Scholar : PubMed/NCBI
37	Feng S, Cao Z and Wang X: Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta. 1836:197–210. 2013.PubMed/NCBI
38	Murray IA, Patterson AD and Perdew GH: Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat Rev Cancer. 14:801–814. 2014. View Article : Google Scholar
39	Powell JB, Goode GD and Eltom SE: The aryl hydrocarbon receptor: A target for breast cancer therapy. J Cancer Ther. 4:1177–1186. 2013. View Article : Google Scholar
40	Kuhajda FP: AMP-activated protein kinase and human cancer: Cancer metabolism revisited. Int J Obes. 32(Suppl 4): S36–S41. 2008. View Article : Google Scholar
41	Faubert B, Vincent EE, Poffenberger MC and Jones RG: The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer Lett. 356:165–170. 2015. View Article : Google Scholar
42	Jeon S-M and Hay N: The double-edged sword of AMPK signaling in cancer and its therapeutic implications. Arch Pharm Res. 38:346–357. 2015. View Article : Google Scholar : PubMed/NCBI
43	Popovic D, Vucic D and Dikic I: Ubiquitination in disease pathogenesis and treatment. Nat Med. 20:1242–1253. 2014. View Article : Google Scholar : PubMed/NCBI
44	Ohta T and Fukuda M: Ubiquitin and breast cancer. Oncogene. 23:2079–2088. 2004. View Article : Google Scholar : PubMed/NCBI
45	Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z and Wei W: Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta. 1855:50–60. 2015.
46	Hills SA and Diffley JF: DNA replication and oncogene-induced replicative stress. Curr Biol. 24:R435–R444. 2014. View Article : Google Scholar : PubMed/NCBI
47	Mazouzi A, Velimezi G and Loizou JI: DNA replication stress: causes, resolution and disease. Exp Cell Res. 329:85–93. 2014. View Article : Google Scholar : PubMed/NCBI
48	Gaillard H, García-Muse T and Aguilera A: replication stress and cancer. Nat Rev Cancer. 15:276–289. 2015. View Article : Google Scholar : PubMed/NCBI
49	Taylor EM and Lindsay HD: DNA replication stress and cancer: cause or cure? Future Oncol. 12:221–237. 2016. View Article : Google Scholar